BioVeda's Teamhas complementary and multi-disciplinary backgrounds and expertise in operations, drug discovery and development, clinical treatment, private equity investment, corporate finance, and mergers and acquisitions. Damien Lim,General Partner, has 20 years experience in private equity and investment banking (PrimePartners, Vickers Ballas, Morgan Grenfell Asia)
Dr. Juanita Fu, General Partner, has more than 15 years of clinical experience with a focus on internal medicine (Kuo Investments, Singapore General Hospital, National University Hospital)
Dr. Kho Choon Joo, General Partner, has more than 15 years experience in early stage investments and research (Lian Huat Group, IQKidz, PSB Academy, Australian Proteome Analysis, Zymogenetics, Calgene)
Fredrik Nyberg,Venture Partner, has 23 years of experience in the medical technologies industry in senior positions in Asia and Europe, and has lived and worked in Asia since 1990 (BioMedical Strategy Consultants, Ohmeda - now separate units of Becton Dickinson and GE Medical)
Veronica Yu, Operations Manager, has more than 15 years experience in private equity operations and administrative functions (Vickers Ballas, Morgan Grenfell Asia)
Our Scientific Advisory Board comprises internationally recognized scientists who provide scientific and clinical development evaluation and guidance. These advisors are actively engaged throughout the investment decision and portfolio management activity of BioVeda.
Professor Chua Nam Hai, Andrew Mellon Professor and Head of Laboratory of Plant Molecular Biology at the Rockefeller University, New York.
Professor Xu Zhi Hong, President, Beijing University, China, former Vice President of Chinese Academy of Sciences. Dr. Lai Por Hsiung, has more than 20 years experience in the biotech and medical technologies industries (President Life Sciences, Kirin Pharmaceuticals, Amgen, Centocor, Sequemat)
Together, the BioVeda Team and the Scientific Advisory Board bring a vast international network of industry, academic, scientific, financial, venture capital, entrepreneurial, government and regulatory relationships.
